The Crohn’s & Colitis Foundation (Foundation) and the American Gastroenterological Association (AGA), in collaboration with Pfizer, Inc., have announced the results of a request for proposal (RFP) to address interventions that aim to improve shared decision-making and promote effective health communication between patients with inflammatory bowel disease (IBD) and their clinicians.
The Crohn’s & Colitis Foundation announced that it received a $5 million pledge from the Litwin family to fund novel, high-risk/high-reward research ideas in the early stage of exploration that could advance the field of inflammatory bowel diseases (IBD) research.
The Crohn’s & Colitis Foundation (the Foundation) celebrates the visionary academic and industry scientists, The Leona M. and Harry B. Helmsley Charitable Trust, IBD patients, and Foundation staff who are partnering to create and sustain IBD Plexus®, a first-of-its-kind research information exchange platform designed to centralize data and biosamples from diverse research studies. The powerful new initiative is designed to advance our understanding of Crohn’s disease and ulcerative colitis, or inflammatory bowel diseases (IBD), and significantly accelerate research driving toward precision medicine and cures for IBD.
The Crohn’s & Colitis Foundation released the following statement today after the New York State Senate passed the Crohn’s & Colitis Fairness Act (S3295).
The Crohn’s & Colitis Foundation (the Foundation) is pleased to announce seven new members of its National Board of Trustees, which oversees the management of the organization’s policies, practices, principles, affairs, funds, and property.
April 20, 2017
Browser not supported
Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options: